87% Lower Cancer Drug Resistance: J&J's RYBREVANT-LAZCLUZE Combo Extends Lung Cancer Survival to 4+ Years

Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer

Chemotherapy-free combination regimen ushers in new era for first-line treatment, with overall survival projected to exceed four years, surpassing monotherapy TKI osimertinib by more than one year

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer

RYBREVANT® combination extends survival and significantly reduces common EGFR and MET resistance mutations seen with osimertinib-based treatment

Rybrevant Plus Lazcluze Associated with Survival Improvement in NSCLC

For some with previously untreated locally advanced or metastatic non-small cell lung cancer Rybrevant plus Lazcluze improved overall survival.

87% Lower Cancer Drug Resistance: J&J's RYBREVANT-LAZCLUZE Combo Extends Lung Cancer Survival to 4+ Years

RYBREVANT plus LAZCLUZE reduces MET amplification to 3% vs 13% with osimertinib in EGFR-mutated NSCLC. Phase 3 MARIPOSA study projects survival beyond 4 years, marking 1-year improvement.